A guide to cooperative research and development agreements
Federal laboratories hold specialized capabilities, equipment, data, and scientific knowledge that can help businesses solve difficult technical problems. A Cooperative Research and Development Agreement, commonly called a CRADA, provides a structured way for a federal laboratory and a nonfederal partner to work together on research and development without creating a conventional procurement contract.
For companies, a CRADA can open access to expertise that would be expensive or impossible to develop independently. For laboratories, it can help move federally funded discoveries toward practical use, strengthen mission-related research, and expose government scientists to real-world technology needs. The arrangement is flexible, but it requires clear objectives, careful intellectual property planning, and a realistic understanding of each party’s responsibilities.
This guide explains how CRADAs function, when they are appropriate, what terms deserve attention, and how an organization can prepare before approaching a federal laboratory. It also places these agreements alongside other technology transfer pathways so that businesses and researchers can choose a partnership model that fits their goals.
What a CRADA does
A CRADA is a formal agreement between one or more federal laboratories and one or more nonfederal parties. The private-sector participant may be a corporation, small business, university, nonprofit organization, state or local government, or another eligible entity. The federal laboratory contributes personnel, facilities, services, equipment, intellectual property, or other resources. The nonfederal participant may contribute funding, staff, materials, equipment, technical information, or access to commercial environments.
The agreement supports collaborative research rather than the government’s purchase of a finished product or service. That distinction matters. A CRADA generally does not require the federal government to pay the partner for completing a defined deliverable, as a procurement contract would. Instead, the parties jointly pursue an agreed research program while retaining their separate legal and operational identities.
The work must align with the laboratory’s mission and available authority. Federal scientists cannot simply accept every proposed project, even when the commercial opportunity appears attractive. The laboratory must consider statutory authority, security requirements, ethics rules, conflicts of interest, export controls, competing commitments, and the availability of staff and facilities.
When a CRADA is a strong fit
A CRADA is especially useful when a company has a technical problem that requires capabilities held by a government laboratory. Examples include advanced materials testing, cybersecurity evaluation, energy systems research, aerospace engineering, medical-device development, environmental monitoring, and high-performance computing. The private partner may already have a product concept but lack a specialized instrument, test environment, or scientific team.
The arrangement can also support the validation of an invention developed inside a federal laboratory. A business might work with government researchers to improve performance, scale a process, conduct field testing, or establish the data needed for regulatory review. In these cases, the CRADA may complement a license for an existing government-owned invention rather than replace it.
A proposed project should have a defined technical question and a credible path to useful results. “Explore artificial intelligence” is too broad for an effective agreement. “Evaluate whether a specified machine-learning method can reduce false positives in a defined sensor dataset under agreed testing conditions” gives the parties a more workable starting point. Specificity helps the laboratory assess feasibility and helps both sides estimate resources, duration, and risk.
Businesses should also examine whether they need access to background intellectual property, controlled data, or laboratory facilities. If the project depends on rights the laboratory cannot provide, negotiations may stall after substantial time has been invested. Early due diligence helps identify those limitations before the parties draft detailed terms.
How the parties divide resources and rights
Each CRADA identifies the contributions expected from the federal laboratory and the collaborating organization. Contributions can be monetary or in kind. A company might provide funding, specialized components, software, or personnel. A laboratory might provide staff time, instruments, test procedures, technical data, and access to a secure facility. The agreement should describe these contributions precisely enough to support budgeting and performance reviews.
Intellectual property provisions are among the most important terms. The agreement should distinguish background inventions and know-how that each party brings to the project from inventions created during the collaboration. It should explain how inventions will be disclosed, who may file patent applications, how costs will be handled, and what rights each participant receives.
Under federal technology transfer rules, a nonfederal CRADA partner may receive an option to negotiate an exclusive or nonexclusive license to an invention made by federal laboratory employees during the collaboration, subject to applicable requirements. The exact rights depend on the agreement, the laboratory, the invention, and the relevant agency policies. A company should not assume that participation automatically grants ownership or unrestricted commercial rights.
Confidential information also requires careful treatment. The company may need to protect trade secrets, unpublished research, customer data, or proprietary designs. The laboratory may need to protect sensitive technical information and comply with disclosure laws. CRADAs can provide mechanisms for protecting certain proprietary information for a defined period, but the parties should identify confidential materials clearly and understand what information may ultimately be subject to public release.
| Partnership mechanism | Typical purpose | Funding pattern | Intellectual property path | Best suited for |
|---|---|---|---|---|
| CRADA | Collaborative research with shared technical participation | Federal and nonfederal contributions, often including in-kind support | Negotiated rights to project inventions and possible license options | Joint development, testing, and validation |
| Patent or technology license | Commercial use of an existing federal invention | License fees, royalties, or negotiated consideration | License to defined patents, software, or know-how | Products based on a mature government technology |
| Technical assistance agreement | Access to laboratory expertise or services | Usually partner-funded work under agency rules | Usually limited rights unless separately negotiated | Focused analysis, testing, or expert support |
| Procurement contract | Government acquisition of goods or services | Government payment for specified deliverables | Rights governed by acquisition regulations and contract terms | Mission requirements with defined outputs |
| Research grant or cooperative agreement | Support for an external research program | Government funding to the recipient | Terms depend on the funding agency and program | Independent or university-led research |
Finding the right federal laboratory
The strongest starting point is a technical need rather than a search for a particular agency. Describe the performance gap, scientific question, target application, required testing, and desired timetable. Then identify laboratories with relevant facilities, publications, patents, technical staff, or prior partnerships. A laboratory directory and technology locator can help narrow the field, while available technology listings may reveal inventions that could support the project.
A concise capability brief is useful when contacting a technology transfer or partnership office. It should summarize the problem, the proposed work, the company’s contribution, the expected public or commercial value, and any sensitive information that should not be disclosed at the initial stage. Avoid sending proprietary details before confidentiality protections are in place.
The first conversation is usually exploratory. Laboratory representatives may discuss mission fit, technical capabilities, facility availability, funding constraints, and possible agreement structures. They may also identify another federal site that is better suited to the work. Because federal laboratories operate through different agencies and regional networks, response times and internal review procedures can vary.
Commercialization planning should begin at the same time as technical discussions. A company should assess its market, manufacturing route, regulatory needs, competitive position, and ability to fund follow-on development. A successful research project does not automatically become a viable product. The parties should define what evidence would justify the next investment decision.
Businesses also need to understand how federal research ownership rules affect commercialization. The Bayh-Dole guidance provides useful context on inventions arising from federally supported research, reporting obligations, and patent-related considerations. A CRADA negotiation should be reviewed alongside the applicable agency policies and any existing license or funding terms.
Negotiating a workable agreement
The statement of work should be detailed enough to guide researchers without making legitimate scientific discovery impossible. It can identify objectives, methods, milestones, technical reviews, deliverables, acceptance criteria, reporting expectations, and decision points. If the project is exploratory, the parties can use staged milestones and periodic go-or-no-go reviews rather than promising a result that cannot be guaranteed.
The agreement should address project management. Name technical and administrative points of contact, establish meeting schedules, describe how changes will be approved, and state what happens if a key employee leaves or a critical facility becomes unavailable. A change-control process prevents informal requests from expanding the project beyond the agreed resources.
Cost and payment provisions deserve equal attention. The parties should specify valuation for staff time, equipment use, materials, travel, subcontracting, and overhead. If the company supplies equipment or software, the agreement should state who owns it, who maintains it, and what happens when the project ends. If either party’s contribution is delayed, the agreement should provide a method for revising milestones.
Publication and communications can be sensitive when federal scientists, universities, and commercial teams work together. The parties should agree on review periods for manuscripts, conference presentations, press releases, and public disclosures. Review should protect confidential information and patent rights without allowing a partner to suppress legitimate scientific communication indefinitely.
Moving from research to commercialization
A CRADA should include a path beyond the research period. The parties can identify anticipated licensing needs, follow-on funding sources, manufacturing partners, regulatory milestones, and data packages required by customers or investors. When a federal invention is central to the project, the company should clarify whether it will need an exclusive field-of-use license, a nonexclusive license, or rights limited to a particular application.
The agreement should also address termination and post-project obligations. A project may end because the technical approach fails, funding changes, a laboratory priority shifts, or the company decides that the market has weakened. Termination terms should cover unfinished work, return or destruction of confidential information, equipment disposition, payment of accrued costs, continued patent cooperation, and survival of licensing or confidentiality provisions.
Careful records support both commercialization and accountability. Maintain invention disclosures, laboratory notebooks, test data, meeting notes, contribution records, and approval documents. These materials can help establish inventorship, support patent filings, explain technical performance, and demonstrate compliance with the agreement.
A CRADA is most effective when it is treated as a managed innovation project rather than a shortcut to government endorsement. The federal laboratory is a research partner, not a guaranteed customer, investor, manufacturer, or regulator. Clear expectations allow the company to benefit from public-sector expertise while preserving a realistic view of commercial risk.
Practical steps before contacting a laboratory
Preparation can shorten the path from an initial inquiry to a serious partnership discussion. Organizations should assemble a small internal team that includes technical, business, legal, and intellectual property perspectives. That team can determine what information may be shared, identify nonnegotiable rights, and evaluate whether the project remains attractive if the research produces only partial results.
A strong proposal connects the company’s need to the laboratory’s mission. It explains why collaboration is necessary, what each party can contribute, how success will be measured, and what public benefit or commercial application may follow. It should also acknowledge uncertainties instead of presenting speculative results as guaranteed outcomes.
Use these actions to prepare for a productive discussion:
- Define the technical problem, intended application, and measurable research objectives.
- Identify federal laboratories with matching expertise, facilities, patents, or testing capabilities.
- Prepare a contribution plan covering funding, personnel, equipment, materials, data, and access.
- Review intellectual property, confidentiality, export control, publication, and licensing requirements.
- Establish realistic milestones, commercialization assumptions, and criteria for continuing the work.
The Federal Laboratory Consortium can help organizations navigate this discovery process by connecting businesses and researchers with federal laboratory capabilities and technology transfer contacts. Once a promising match is identified, the laboratory’s designated partnership or technology transfer office can explain agency-specific procedures and begin the formal evaluation.
A well-prepared CRADA creates a bridge between technical expertise and market application. Begin with a focused problem, identify the right federal partner, and enter negotiations with a clear plan for contributions, intellectual property, information protection, and follow-on commercialization. That preparation gives both sides a stronger basis for turning collaborative research into a useful technology.